Neogenomics (NEO) Inventory (2010 - 2026)

Neogenomics (NEO) has 17 years of Inventory data on file, last reported at $27.1 million in Q2 2026.

• Quarterly Inventory fell 20.58% year-over-year to $27.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $27.1 million (down 20.58% YoY) and the FY2025 annual result came in at $28.6 million, up 6.8% from the prior year.
• Inventory declined to $27.1 million in Q2 2026, from $29.8 million in the prior quarter.
• In the past five years, Inventory ranged from a high of $34.2 million in Q2 2025 to a low of $20.3 million in Q1 2024.
• A 5-year average of $25.8 million and a median of $24.4 million in 2023 frame the typical range for Inventory.
• Annual changes were most pronounced in 2025 — Inventory jumped 47.2% — and 2026, when it declined 20.58%.
• Tracing NEO's Inventory over 5 years: stood at $24.3 million in 2022, then dropped by 0.5% to $24.2 million in 2023, then climbed by 10.73% to $26.7 million in 2024, then grew by 6.8% to $28.6 million in 2025, then fell by 5.0% to $27.1 million in 2026.
• The last three Inventory figures came in at $27.1 million (Q2 2026), $29.8 million (Q1 2026), and $28.6 million (Q4 2025), per Business Quant data.